Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 4/20 | 0.55 |
| ▸ | F10 | P00742 | 12/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5068364 | 1.00 | NPY5R (0.55) | NPY5RF10MEN1NPC1RAB9A | |
| SCHEMBL14191248 | 0.90 | F10 (0.65) | NPY5RF10 | |
| SCHEMBL14191250 | 0.90 | F10 (0.57) | NPY5RF10LMNATP53GAA | |
| SCHEMBL14191249 | 0.87 | F10 (0.59) | NPY5RF10 | |
| SCHEMBL14191247 | 0.86 | F10 (0.56) | NPY5RF10 | |
| SCHEMBL5071102 | 0.85 | NPY5R (0.55) | NPY5RF10MEN1KMT2ATSHR | |
| SCHEMBL5071105 | 0.85 | NPY5R (0.55) | NPY5RF10MEN1KMT2ATSHR | |
| SCHEMBL14191275 | 0.84 | NPY5R (0.55) | NPY5RF10NPC1RAB9ALMNA | |
| SCHEMBL14191313 | 0.83 | NPY5R (0.54) | NPY5RF10RAB9ALMNATSHR | |
| SCHEMBL14191279 | 0.82 | NPY5R (0.53) | NPY5RF10LMNATSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7375119-B2 | Amide type carboxamide derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-05-20 | — | — | US | disclosed |
| US-20060287329-A1 | Amide type carboxamide derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2006-12-21 | — | — | US | disclosed |
| EP-1666455-A1 | AMIDE TYPE CARBOXAMIDE DERIVATIVE | TANABE SEIYAKU CO., LTD. (JP) | 2006-06-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287329-A1 | Amide type carboxamide derivative | F12, F11, F13A1 | NPY5R 42/4885F10 7/4885MEN1 1337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.